Speaker
Description
Alzheimer's and Parkinson's disease represent two of the most prevalent neurodegenerative diseases with dramatic socio-economic impacts for governments and healthcare systems to address. Currently, excepting the modest effects of Aducanumab in AD, there are no disease modifying therapies for either disease. However, the development of future disease modifying drugs represents a tremendously active area for the pharmaceutical industry with a large number of clinical trials under way. Imaging biomarkers are central to these clinical trials and provide important readouts of relevant disease pathology and the impact of novel therapies. This talk will review the biomarkers that are currently deployed in clinical trials and those that are in development for these devastating neurodegenerative diseases.
